Apellis Pharmaceutical’s pegcetacoplan has shown hints of efficacy in a handful of patients with rare kidney diseases in a Phase II trial, five months after the compound faced a clinical setback in ALS.
Pegcetacoplan won US approval under the brand name Empaveli in 2021 for paroxysmal nocturnal hemoglobinuria. The active ingredient also forms the basis of Apellis’ Syfovre, which was authorized for geographic atrophy in February this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.